Bastakis George G, Stavrakakis Anastasios, Nikolaos Avgoustinakis, Dimopoulos Dimitris, Pappas George
Ophthalmology Clinic, Medical Retina & Vitreoretinal Surgery Department, Venizeleio Hospital of Crete, Knossos Avenue 44, Heraklion of Crete, Greece.
Case Rep Ophthalmol Med. 2018 Nov 18;2018:4614802. doi: 10.1155/2018/4614802. eCollection 2018.
We present a case of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of this rare and challenging case in which the implant could not be removed. A 50-year-old woman with a history of branch retinal vein occlusion in the right eye was treated with intravitreal dexamethasone implant injection for macular oedema. Four days after injection, the patient was admitted to the department with acute pain, decreased vision, and redness. A diagnosis of acute post-intravitreal injection endophthalmitis was made. A 23-guage (23G) vitrectomy was performed immediately to remove the implant, and a vitreous tap for culture and polymerase chain reaction was acquired during the procedure. We were unable to remove the dexamethasone implant during the vitrectomy because of dense membrane formation. At the end of the procedure, we injected intravitreal antibiotics (vancomycin and amikacin), and the patient was treated with fortified topical antibiotics and steroids. At the time of writing, 5 years later, the patient retains a best corrected visual acuity of 10/10 (6/6) with dexamethasone implant therapy maintenance. Intravitreal dexamethasone implant-associated endophthalmitis is a rare and challenging condition. Immediate 23G pars plana vitrectomy, even without removal of the implant, can lead to favourable visual results.
我们报告一例玻璃体内注射地塞米松植入剂后发生急性眼内炎的病例,并讨论了这一罕见且具有挑战性的病例的处理方法,该病例中植入物无法取出。一名50岁女性,右眼有视网膜分支静脉阻塞病史,因黄斑水肿接受玻璃体内地塞米松植入剂注射治疗。注射后四天,患者因急性疼痛、视力下降和眼红入院。诊断为玻璃体内注射后急性眼内炎。立即进行了23G玻璃体切除术以取出植入物,并在手术过程中抽取玻璃体进行培养和聚合酶链反应。由于致密膜形成,我们在玻璃体切除术中无法取出地塞米松植入物。手术结束时,我们注射了玻璃体内抗生素(万古霉素和阿米卡星),患者接受了强化局部抗生素和类固醇治疗。在撰写本文时,5年后,患者通过维持地塞米松植入剂治疗,最佳矫正视力保持在10/10(6/6)。玻璃体内地塞米松植入剂相关的眼内炎是一种罕见且具有挑战性的疾病。立即进行23G平部玻璃体切除术,即使不取出植入物,也可带来良好的视力结果。